Anika Therapeutics ANIK Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$5.06M— | $0+100% | -$2.33M+41.3% | -$3.97M+18.5% | -$4.87M+77.7% | ||
| $1.41M+6.8% | $1.32M-5.2% | $1.39M+8.7% | $1.28M-7.4% | $1.38M-11.3% | ||
| $6.64M+170% | $2.46M+11.0% | $2.22M-13.1% | $2.55M-11.0% | $2.86M+27.0% | ||
| $108K+532% | -$25K-933% | $3K+200% | -$3K-117% | $18K-92.3% | ||
| $52K— | —— | $451K+120% | $205K-31.7% | $300K+111% | ||
| $2.18M— | —— | -$1.29M— | —— | -$3.03M— | ||
| $5.41M— | —— | —— | -$1.73M-231% | -$523K— | ||
| $745K-15.1% | $877K+280% | $231K+121% | -$1.11M-2,468% | $47K+139% | ||
| -$1.34M— | —— | —— | -$2.16M+30.0% | -$3.09M-230% | ||
| $1.73M+232% | -$1.31M-499% | -$219K+78.1% | -$1M-593% | $203K+476% | ||
| $1.19M— | —— | -$21K+95.2% | -$435K-3,246% | -$13K-113% | ||
| $464K-7.0% | $499K+0.8% | $495K+1.0% | $490K-15.1% | $577K-2.0% | ||
| -$4.85M-205% | $4.64M-32.5% | $6.87M+3,735% | -$189K-45.4% | -$130K-108% | ||
| $1.43M+121% | $648K-65.7% | $1.89M+28.6% | $1.47M-48.1% | $2.82M+116% | ||
| $0— | —— | —— | —— | $4.5M— | ||
| -$1.24M— | —— | -$1.73M— | —— | $1.67M+228% | ||
| $8.69M+57.6% | $5.51M— | —— | —— | $3.97M-28.8% | ||
| $1.66M+41,325% | $4K-69.2% | $13K-84.1% | $82K-94.4% | $1.47M+1,830% | ||
| -$10.35M-96.0% | -$5.28M-40,508% | -$13K— | $0+100% | -$5.44M-1.6% | ||
| -$29K— | —— | —— | $345K+219% | $108K+183% | ||
| -$16.46M— | —— | $4.82M+2,464% | -$204K+94.6% | -$3.79M+27.3% | ||
| —— | $269K0.0% | $269K0.0% | $269K0.0% | $269K-73.1% | ||
| $52K— | —— | $451K+120% | $205K-31.7% | $300K— | ||
| $1.73M+232% | -$1.31M-499% | -$219K+78.1% | -$1M-593% | $203K+476% | ||
| $1.03M+21.1% | $852K-24.4% | $1.13M-62.6% | $3.01M+262% | $832K-95.5% | ||
| $464K-7.0% | $499K+0.8% | $495K+1.0% | $490K-15.1% | $577K-2.0% | ||
| $192K-77.3% | $846K+446% | $155K-52.7% | $328K— | $0— | ||
| $0— | —— | —— | —— | $4.5M— | ||
| $0— | $0-100% | $12K-91.2% | $136K-34.9% | $209K-17.1% | ||
| $55K-91.3% | $630K— | —— | $318K-36.7% | $502K-3.6% | ||
| -$29K— | —— | —— | $345K+219% | $108K+183% | ||
| -$468K+0.6% | -$471K+1.9% | -$480K-0.8% | -$476K+16.3% | -$569K+1.4% | ||
| $179K-62.1% | $472K+497% | $79K-34.7% | $121K-46.0% | $224K— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$24K-143% | $56K-26.3% | $76K-84.1% | $479K+238% | -$346K-314% | ||
| —— | $269K0.0% | $269K0.0% | $269K0.0% | $269K-73.1% | ||
| -$6.28M-257% | $3.99M-19.9% | $4.98M+401% | -$1.66M+43.9% | -$2.95M— | ||
| -$6.28M-257% | $3.99M-19.9% | $4.98M+401% | -$1.66M+43.9% | -$2.95M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Anika Therapeutics generate?
- Anika Therapeutics (ANIK) generated $6.5M in operating cash flow over the trailing twelve months.
- What is Anika Therapeutics's free cash flow?
- After $5.4M of capital expenditures, Anika Therapeutics's free cash flow was $1.0M over the trailing twelve months, up 105.4% year over year.
- Where does Anika Therapeutics's cash flow data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
